Eli Lilly And Co Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ELI LILLY AND CO, and when can generic versions of ELI LILLY AND CO drugs launch?
ELI LILLY AND CO has seven approved drugs.
There are nineteen US patents protecting ELI LILLY AND CO drugs. There is one tentative approval on ELI LILLY AND CO drugs.
There are three hundred and eighty-two patent family members on ELI LILLY AND CO drugs in fifty-six countries and forty-four supplementary protection certificates in eighteen countries.
Summary for Eli Lilly And Co
| International Patents: | 382 |
| US Patents: | 19 |
| Tradenames: | 10 |
| Ingredients: | 6 |
| NDAs: | 7 |
| Drug Master File Entries: | 37 |
| Patent Litigation for Eli Lilly And Co: | See patent lawsuits for Eli Lilly And Co |
| PTAB Cases with Eli Lilly And Co as petitioner: | See PTAB cases with Eli Lilly And Co as petitioner |
| PTAB Cases with Eli Lilly And Co as patent owner: | See PTAB cases with Eli Lilly And Co as patent owner |
Drugs and US Patents for Eli Lilly And Co
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | 12,071,423 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Eli Lilly And Co | AXIRON | testosterone | SOLUTION, METERED;TRANSDERMAL | 022504-001 | Nov 23, 2010 | DISCN | Yes | No | 8,993,520 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Eli Lilly And Co | ZEPBOUND (AUTOINJECTOR) | tirzepatide | SOLUTION;SUBCUTANEOUS | 217806-001 | Nov 8, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | RX | Yes | Yes | 12,071,423 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Eli Lilly And Co | MOUNJARO (AUTOINJECTOR) | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-005 | May 13, 2022 | RX | Yes | Yes | 9,474,780 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | 11,053,214 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Eli Lilly And Co | ZEPBOUND (AUTOINJECTOR) | tirzepatide | SOLUTION;SUBCUTANEOUS | 217806-004 | Nov 8, 2023 | RX | Yes | Yes | 11,357,820 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Eli Lilly And Co
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,683,235 | ⤷ Sign Up |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,594,358 | ⤷ Sign Up |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,590,213 | ⤷ Sign Up |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-006 | Dec 23, 1992 | 4,018,895 | ⤷ Sign Up |
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | 8,748,459 | ⤷ Sign Up |
| Eli Lilly And Co | SARAFEM | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-007 | Jul 6, 2000 | 5,744,501*PED | ⤷ Sign Up |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-003 | Jun 15, 1999 | 6,960,577 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ELI LILLY AND CO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Topical Solution | 30 mg/1.5 mL | ➤ Subscribe | 2013-01-29 |
International Patents for Eli Lilly And Co Drugs
Supplementary Protection Certificates for Eli Lilly And Co Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2288610 | LUC00027 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: BARICITINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215 |
| 3242887 | 122023000012 | Germany | ⤷ Sign Up | PRODUCT NAME: TIRZEPATIDE UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON; REGISTRATION NO/DATE: EU/1/22/1685 20220915 |
| 3242887 | LUC00296 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: TIRZEPATIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/22/1685 20220919 |
| 2379528 | PA2019004 | Lithuania | ⤷ Sign Up | PRODUCT NAME: ABEMACIKLIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1307 20180927 |
| 3242887 | C03242887/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: TIRZEPATID; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68726 02.11.2022 |
| 2288610 | 1790035-8 | Sweden | ⤷ Sign Up | PRODUCT NAME: BARICITINIB; REG. NO/DATE: EU/1/16/1170 20170215 |
| 2379528 | 300969 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ABEMACICLIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/18/1307 20181001 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
